Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

Laura Samples, Sirin Khajaviyan, Sara Keshmiri, Ryan S. Basom, Ryan C Lynch, Vikram Raghunathan, Mengyang Di, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Christina Poh, Stephanie Louie, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 6785.

https://doi.org/10.1182/blood-2024-211971

Published: 2024

Journal Articles

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Christina Poh, Xueyan Chen, Jenna M. Voutsinas, Edus H. Warren, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Sindhu Cherian, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2024-205892

Published: 2024

Journal Articles

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Thomas M Kuczmarski, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian G. Till, Vikram Raghunathan, Yolanda D Tseng, Hongyan Du, Jacquelin Vandermeer, Alyssa Kelly, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal, Ryan C Lynch

Blood (2024) 144 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2024-208412

Published: 2024

Journal Articles

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2024-206601

Published: 2024

Journal Articles

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Blood (2024) 144 (Supplement 1): 652.

https://doi.org/10.1182/blood-2024-202153

Published: 2024

Journal Articles

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Jordan S Goldstein, Mark Roschewski, Won-Seog Kim, Sang Eun Yoon, Seok Jin Kim, Jason R. Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob Chabon, Davide Rossi, Wyndham H. Wilson, David Kurtz, Ash A. Alizadeh

Blood (2024) 144 (Supplement 1): 651.

https://doi.org/10.1182/blood-2024-211068

Published: 2024

Journal Articles

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Blood (2024) 144 (Supplement 1): 3051.

https://doi.org/10.1182/blood-2024-206512

Published: 2024

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2024-206047

Published: 2024

Journal Articles

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Blood (2024) 144 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2024-200719

Published: 2024

Journal Articles

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Carrie I Ho, Neena Kennedy, Mengyang Di, Ajay K. Gopal, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Heather Rasmussen, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Stephen D. Smith

Blood (2024) 144 (Supplement 1): 783.

https://doi.org/10.1182/blood-2024-208269

Published: 2024

Journal Articles

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Carrie I Ho, Mengyang Di, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Mazyar Shadman, Stephen D. Smith, Brian G. Till, Paul S Martin, Chaitra S. Ujjani, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1661.2.

https://doi.org/10.1182/blood-2024-204154

Published: 2024

Journal Articles

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Jennifer J. Huang, Laura Samples, Margie Fredericks, Stephanie Louie, Ramya Pulluru, Christine Crider, Mehrdad Shakib-Azar, Neena Kennedy, Vikram Raghunathan, Christina Poh, Mengyang Di, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Ryan C. Lynch, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 4634.2.

https://doi.org/10.1182/blood-2024-204491

Published: 2024

Journal Articles

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 460.

https://doi.org/10.1182/blood-2024-200992

Published: 2024

Journal Articles

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Christina Poh, Jenna M. Voutsinas, Ivan Huang, Edus H. Warren, Caitlin A. Crimp, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Michi M. Shinohara, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2024-194018

Published: 2024

Journal Articles

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Mengyang Di, Carrie I Ho, Stephen D. Smith, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Christina Poh, Vikram Raghunathan, Brian G. Till, Edus H. Warren, Ajay K. Gopal, Stephanie J. Lee

Blood (2024) 144 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2024-201827

Published: 2024

Journal Articles

Toward a cure for cHL without chemotherapy

Ryan C. Lynch

Blood (2024) 143 (9): 741–742.

https://doi.org/10.1182/blood.2023023108

Published: 2024

Journal Articles

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Mazyar Shadman, Brian G Till, Vikram Raghunathan, Edus H Warren, Jordan Gauthier, Stephen D Smith, Taran Gujral, Chihiro Morishima, Qian Wu, Jenna M Voutsinas, Amy Sperling, Joshua Dizon, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2023-183034

Published: 2023

Journal Articles

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Jordan Goldstein, Won Seog Kim, Sang Eun Yoon, Seok Jin Kim, Mark Roschewski, Jason Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob J. Chabon, Davide Rossi, Wyndham H Wilson, Maximilian Diehn, Ash A. Alizadeh, David M. Kurtz

Blood (2023) 142 (Supplement 1): 187.

https://doi.org/10.1182/blood-2023-187759

Published: 2023

Journal Articles

Intent to Treat Allogeneic Stem Cell Transplantation Outcomes in Relapsed/Refractory T-Cell Lymphomas

Christina Poh, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Michi M Shinohara, Phuong T Vo, Mazyar Shadman, Chaitra S Ujjani, Ryan C Lynch, Brian G Till, Stephen D Smith, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2023-184314

Published: 2023

Journal Articles

Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors

Laura Samples, Sirin Khajaviyan, Ryan C Lynch, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Hania Shakalia, Stephanie Louie, David G Maloney, Christina Poh, Brian G Till, Stephen D Smith, Ajay K Gopal, Chaitra S Ujjani, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2023-186775

Published: 2023

NARROW

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Toward a cure for cHL without chemotherapy

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Intent to Treat Allogeneic Stem Cell Transplantation Outcomes in Relapsed/Refractory T-Cell Lymphomas

Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only